


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Use of the compounds of the formula I

in which

5



X denotes CH or N,

R¹ denotes H, A, Hal, (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,

R² denotes (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF₃,

R³, R⁴ denote H, (CH₂)<sub>n</sub>CO₂R⁵, (CH₂)<sub>n</sub>COHet, (CH₂)<sub>n</sub>CON(R⁵)₂, (CH₂)<sub>n</sub>OOO(CH₂)<sub>n</sub>Het, CHO, (CH₂)<sub>n</sub>OR⁵, (CH₂)<sub>n</sub>Het, (CH₂)<sub>n</sub>N(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)<sub>n</sub>NHOA, (CH₂)<sub>n</sub>N(R⁵)Het, (CH₂)<sub>n</sub>CH=N-Het, (CH₂)<sub>n</sub>OOOR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OCF₃, (CH₂)<sub>n</sub>N(R⁵)C(R⁵)HOOOR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂COHet, (CH₂)<sub>n</sub>N(R⁵)CH₂Het, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂Het, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂N(R⁵)CH₂OOOR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂OR⁵, (CH₂)<sub>n</sub>N(R⁵)CH₂CH₂N(R⁵)₂, CH=CHOOOR⁵, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)<sub>n</sub>N(R⁵)Ar, (CH₂)<sub>n</sub>N(OOOR)COOR⁵, (CH₂)<sub>n</sub>N(CONH₂)OOOR⁵, (CH₂)<sub>n</sub>N(CONH₂)CONH₂, (CH₂)<sub>n</sub>N(CH₂OOOR)COOR⁵, (CH₂)<sub>n</sub>N(CH₂CONH₂)OOOR⁵, (CH₂)<sub>n</sub>N(CH₂CONH₂)CONH₂, (CH₂)<sub>n</sub>CHR⁵COR⁵, (CH₂)<sub>n</sub>CHR⁵OOOR⁵, (CH₂)<sub>n</sub>CHR⁵CH₂OR⁵, where in each case one of the radicals R³ or R⁴ has the meaning H,

R⁵ denotes H or A

A denotes straight-chain or branched alkyl or cycloalkyl having 2 to 4 C atoms, having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het preferably denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR<sup>S</sup>, OOCR<sup>S</sup>, COOR<sup>S</sup>, CON(R<sup>S</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>S</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

and salts and solvates, enantiomers and racemates thereof for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5 HT receptors.

2. (Original) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.
3. (Currently Amended) Use of compounds according to Claim 1 ~~or~~ 2 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT<sub>2A</sub> receptor-antagonistic action.
4. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~2 or~~ 3 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive

compulsive disorder (OCD).

5. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.
6. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub> or CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar.
7. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R<sup>4</sup> denotes H.
8. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.
9. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which X has the meaning CH.
10. (Original ) Use of the compounds of the formula (a) to (o) according to Claim 1:  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]- (a)  
(4-methylpiperazin-1 -yl)amine  
  
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]- (b)  
ethyl}morpholine

- 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine (c)
- 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol (d)
- 1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (e)
- 1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (f)
- 1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine (g)
- N<sup>1</sup>-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine (h)
- 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol (i)
- [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine (j)
- 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol (k)
- 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam (l)
- 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine (m)
- 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (n)
- [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine (o)

and salts and solvates thereof.